Tumour volumes were markedly reduced in mice with shTFRC‐modified tumours receiving anti‐PD‐1 antibody treatment, compared with those in mice with parental Hepa1‐6 cell tumours also treated with the anti‐PD‐1 antibody (1171.13 ± 477.89 mm3 vs. 2314.61 ± 699.20 mm3, p = 0.008, Figure 5B). The gene discussed is PDCD1; the disease is neoplasm.